source
- BrightGene advances obesity drug toward Chinese approval, eyes Western data and partnersBrightGene has submitted its obesity GLP-1 candidate to Chinese regulators after reporting strong Phase 3 results. The company says data from Western trials are expected to be even more robust, wh…
- Former FDA AI regulator says biopharma is misreading agency's guidance, leading to overly cautious approachesTala Fakhouri, who wrote AI policy at the FDA, left the agency last summer and now serves as chief AI and regulatory strategy officer at contract research organization Parexel. She says biopharma…